ライフサイエンスコーパス: alendronate

1 ed pharmacologically with the bisphosphonate alendronate.

2 quiring farnesylation, which is inhibited by alendronate.

3 ower mean BMD before ADT, or a lower cost of alendronate.

4 mab compared with those receiving placebo or alendronate.

5 ity that is greater than in those continuing alendronate.

6 raloxifene (HR, 1.18 [CI, 0.96 to 1.46]) and alendronate.

7 ceiving teriparatide than in those receiving alendronate.

8 prevented and improved with once-weekly oral alendronate.

9 e continuing (19%) and discontinuing (18.9%) alendronate.

10 fractures compared with those who continued alendronate.

11 n-7-ol (EM652), and the aminobisphosphonate, alendronate.

12 ectomized animals treated with E2, EM652, or alendronate.

13 luate the efficacy and safety of (64)Cu-DOTA-alendronate.

14 nts were randomly assigned to receive either alendronate (10 mg per day) or calcitriol (0.5 microg pe

15 as B3, in femurs of adult mice injected with alendronate (10 microg/100 g/wk) for 8 weeks.

16 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate).

17 intestinal tract symptoms (alendronate vs no alendronate, 15.6 [95% CI, 11.6-21.0] vs 12.9 [95% CI, 9

18 D over 48 weeks were significantly larger on alendronate (20% [14%-25%]) than placebo (7% [5%-9%]) (P

19 D over 48 weeks were significantly larger on alendronate [20% (14%, 25%)] than placebo [7% (5%, 9%),

20 is there were 133 cases of AMD reported with alendronate, 20 with ibandronate, and 14 with risedronat

21 In all, 75 subjects (34 alendronate, 25 calcitriol, 16 reference) participated.

22 le-blind, 2-arm, placebo-controlled trial of alendronate (40 mg/d) was performed in adults with GD wh

23 Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or p

24 served more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 p

25 rs of bone turnover compared with continuing alendronate: 55.6% (P<.001) for C-telopeptide of type 1

26 al year with either placebo (60 subjects) or alendronate (59 subjects).

27 ncer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-bli

28 bo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide

29 utaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months,

30 of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2-yea

31 Our hypothesis is that alendronate, a member of the N-containing bisphosphonate

32 thylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand).

33 sulated alendronate (PLN-alen), but not free alendronate, abrogated PLN-induced tumor growth and incr

34 (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the m

35 zed a novel, fluorescently labeled analog of alendronate (AF-ALN).

36 Women who discontinued alendronate after 5 years showed a moderate decline in B

37 acilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone

38 as been fabricated for controlled release of alendronate (AL).

39 (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been proposed as sensitisers in

40 icated a functionalized GNPs conjugated with alendronate (ALD), of the bisphosphonate group.

41 eta1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone.

42 aims to explore the clinical efficacy of 1% alendronate (ALN) gel as a local drug delivery system in

43 The response of osteoclasts to alendronate (ALN) in tumor necrosis factor-transgenic (T

44 Alendronate (ALN) increases alveolar bone density with s

45 Sodium alendronate (ALN) is an aminobisphosphonate and potent i

46 Alendronate (ALN) is an antiresorptive agent widely used

47 The traditional bisphosphonate (BP) alendronate (Aln) or IG9402, a BP analog that does not i

48 he treatment of bisphosphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43

49 Alendronate (ALN), a member of the amino-bisphosphonate

50 LT) model of OA and evaluated the effects of alendronate (ALN), a potent inhibitor of bone resorption

51 Alendronate (ALN), an aminobisphosphonate, is known to i

52 Alendronate (ALN), an aminobisphosphonate, is known to s

53 Alendronate (ALN), an influential member of the bisphosp

54 let rich fibrin (PRF) and bisphosphonates as alendronate (ALN).

55 onth periods without parathyroid hormone, or alendronate alone for 15 months.

56 ull-length parathyroid hormone (1-84) alone, alendronate alone, or both combined.

57 a significantly lower risk of fracture than alendronate alone.

58 ssion and tumor growth can be reversed using alendronate, an immune modulatory drug.

59 s developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (P > .99).

60 s developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (p>0.99).

61 compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo).

62 irty-eight percent of participants receiving alendronate and 33% receiving placebo had LOBP (P = .81)

63 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide.

64 ompared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and

65 ompared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at

66 s in fracture risk reduction attributable to alendronate and alendronate cost.

67 the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and a

68 and quinapril), non-vertebral fracture (for alendronate and calcitonin), psychiatric hospitalization

69 ort of 108 participants in a trial comparing alendronate and calcitriol for prevention of posttranspl

70 chemo-immunotherapy strategies to co-deliver alendronate and chemotherapy for the treatment of cancer

71 s not cost-effective, assuming U.S. costs of alendronate and currently available estimates of alendro

72 ocalcification targeting specificity of DOTA-alendronate and elucidate the histologic and ultrastruct

73 Elderly women being treated with alendronate and estrogen had a significantly decreased p

74 Raloxifene is as effective as alendronate and may remain an option in the prevention o

75 Both regimens, weekly alendronate and monthly ibandronate, improve bone mass a

76 e was 0.068 +/- 0.21 and 0.015 +/- 0.034 for alendronate and placebo groups, respectively (P =.001).

77 in SPMCh PC(20) value was 0.50 and 0.27 with alendronate and placebo, respectively (P = .62).

78 Alendronate and raloxifene are among the most popular an

79 Alendronate and raloxifene have a similar hip fracture r

80 Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continu

81 Bisphosphonates such as alendronate and zoledronate are blockbuster drugs used t

82 irtually abolished by OPG treatment, whereas alendronate and zoledronate only partially reduced these

83 We used bisphosphonate inhibitors, alendronate and zoledronate, that inhibit the consumptio

84 Long-term alendronate and zoledronic acid therapies reduce fractur

85 Mice were treated with prednisolone, alendronate, and both in combination for up to 6 months.

86 5 to 0.913 +/- 0.026 g/cm(2), P < 0.001 with alendronate, and from 0.898 +/- 0.024 to 0.949 +/- 0.027

87 ystemic disease was managed with prednisone, alendronate, and losartan.

88 Src inhibitor dasatinib, the bisphosphonate alendronate, and the osteoclast-specific apoptosis-induc

89 Although in this study oral alendronate appears to be well tolerated in patients wit

90 ed with alendronate; when women treated with alendronate are switched to denosumab, there is an incre

91 se of this study was to evaluate (64)Cu-DOTA-alendronate as a mammary microcalcification-targeting PE

92 groups: those receiving placebo for 3 years; alendronate at a dose of 1, 5, or 10 mg per day for 3 ye

93 se of 1, 5, or 10 mg per day for 3 years; or alendronate at a dose of 20 mg per day for 2 years, foll

94 n increase compared with those who initiated alendronate at baseline.

95 ralized and demineralized bone was soaked in alendronate at concentrations of 0.002, 2.0, and 2,000 n

96 ronate use; no patients had previously taken alendronate at the time of prednisolone initiation.

97 The clinical findings that alendronate blunted the anabolic effect of human parathy

98 In men treated with alendronate, bone mineral density increased over 1 year

99 ns appear to be maintained or increased with alendronate but lost if parathyroid hormone is not follo

100 Use of alendronate, but not estrogen, was associated with less

101 oaked mineralized bone contained measureable alendronate, but the substance was removed by deminerali

102 nd no differences in outcomes were noted for alendronate, calcitonin, glipizide, or quinapril.

103 We sought to determine whether alendronate can reduce LABA-associated LOBP in inhaled c

104 .09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0.69, 0.22 and 0.06 e

105 Biodistribution studies revealed tissue alendronate concentrations peaking within the first hour

106 Confocal analysis with carboxyfluorescein-alendronate confirmed the microcalcification binding spe

107 formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTN

108 of the synthesized polymers: PLGA-b-PEG and alendronate-conjugated polymer PLGA-b-PEG-Ald, which ens

109 sk reduction attributable to alendronate and alendronate cost.

110 ethanol (SIM-EtOH); 2) 0.5 mg simvastatin in alendronate-cyclodextrin conjugate (SIM-ALN-CD); 3) EtOH

111 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment.

112 Treatment with 10 mg of alendronate daily for 10 years produced mean increases i

113 An investigation of the chemical behavior of alendronate derivatives led to development of practical

114 Alendronate derivatives were evaluated as potential prod

115 he microcalcification binding specificity of alendronate derivatives.

116 similar in both groups and one patient with alendronate developed a new vertebral fracture.

117 n of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, i

118 active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5)

119 dronate and currently available estimates of alendronate efficacy in osteopenic women.

120 Prednisolone alone and in combination with alendronate enhance functionally glycosylated alpha-dyst

121 Good evidence suggests that alendronate, etidronate, ibandronate, risedronate, zoled

122 Men receiving alendronate for 2 years experienced a mean 6.7% (+/- 1.2

123 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate

124 Our long-term goal is to develop (64)Cu-DOTA-alendronate for the detection and noninvasive differenti

125 Herein, we evaluated prednisolone and alendronate for their therapeutic potential in the FKRPP

126 ate cancer, a BMD test followed by selective alendronate for those with osteoporosis is a cost-effect

127 al women with osteoporosis were treated with alendronate for up to 10 years.

128 gest that for many women, discontinuation of alendronate for up to 5 years does not appear to signifi

129 atients taking oral bisphosphonates, such as alendronate, for osteoporosis is uncertain and warrants

130 whether the demineralization process removes alendronate from allograft bone.

131 ization process effectively removed residual alendronate from allograft bone.

132 (P = .005) in spine BMD was observed in the alendronate group (0.09 +/- 0.03 g/cm2 SD from baseline)

133 curred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidenc

134 f 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.00

135 alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 o

136 fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in

137 d more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001).

138 triol group (P< or =0.001) and by 32% in the alendronate group (P< or =0.001).

139 lcitriol group and 7 percent of those in the alendronate group (P=0.01).

140 ad decreased by a mean of 0.7 percent in the alendronate group and 1.6 percent in the calcitriol grou

141 ck decreased by a mean of 1.7 percent in the alendronate group and 2.1 percent in the calcitriol grou

142 4 years), there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group, co

143 rathyroid hormone group as compared with the alendronate group and no significant difference between

144 ase of 31 percent in the parathyroid hormone-alendronate group as compared with 14 percent in the par

145 in the cyclic-therapy group, and four in the alendronate group had new or worsening vertebral deformi

146 tures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate

147 f 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in

148 icantly among the groups (6.8 percent in the alendronate group, 3.6 percent in the calcitriol group,

149 s, 14 in the ibandronate group and 19 in the alendronate group, completed the trial.

150 es in the alendronate group and 73 in the no-alendronate group, corresponding to incidence rates of 9

151 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with ro

152 percent (P=0.03 for the comparison with the alendronate group; P=0.15 for the comparison with the ca

153 omosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 eve

154 Similarly, those discontinuing alendronate had increased serum markers of bone turnover

155 hic cardiac calcification phenotype, whereas alendronate had no significant effect.

156 Alendronate has higher risk for AFF (HR 1.51, 95% CI 1.2

157 nts with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treat

158 nvertebral fractures than those who received alendronate (HR, 1.40, [CI, 1.20 to 1.63]).

159 The reported odds ratios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95%

160 dications are for treatment of osteoporosis (alendronate, ibandronate, and risedronate) and treatment

161 c prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover

162 Once-weekly alendronate improves bone mass and is well tolerated in

163 ion initiators: a study of raloxifene versus alendronate in 1-year nonvertebral fracture risk, a stud

164 trolled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages

165 developed and validated to quantify residual alendronate in allograft bone.

166 ashion for 12 months, followed by open-label alendronate in both groups.

167 rats showed specific binding of (64)Cu-DOTA-alendronate in mammary glands and mammary tumors.

168 Encapsulating alendronate in PLN reversed these effects on myeloid cel

169 he safety and efficacy of 48 and 96 weeks of alendronate in the United States and Brazil.

170 of events, these results support the use of alendronate in this patient group.

171 (control) or diets containing etidronate or alendronate in three different concentrations (experimen

172 Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone m

173 dronate monotherapy in year 1 continued with alendronate in year 2.

174 eived combination therapy in year 1 received alendronate in year 2; those who had received alendronat

175 Women in the original placebo group received alendronate in years 4 and 5 and then were discharged.

176 We found that alendronate increased gene and protein expression of eph

177 the highly specific pharmaceutical inhibitor alendronate inhibited beta2AR down-regulation.

178 ne-targeted antiresorptives bis-enoxacin and alendronate inhibited increases in oxidative stress caus

179 Conclusion:(64)Cu-DOTA-alendronate is a promising PET imaging agent for the sen

180 Alendronate is a useful adjunctive therapy in combinatio

181 in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells to destru

182 l oxide surface and the phosphate residue of alendronate, leading to formation of homogenous drug dis

183 of oral bisphosphonate use were compared to alendronate levels in DBM procured from donors without a

184 Alendronate levels in DBM procured from tissue donors wi

185 Although it has been suggested that alendronate might improve bone mineral density (BMD) in

186 ; low SOE) and clinical vertebral fractures (alendronate; moderate SOE) but not nonvertebral fracture

187 lendronate in year 2; those who had received alendronate monotherapy in year 1 continued with alendro

188 levels in calcitriol-treated patients makes alendronate more attractive for the prevention of bone l

189 icate stronger suppressive effects of E2 and alendronate on bone formation activity and that ovariect

190 r systemically applied antiresorptive agent (alendronate) on simvastatin-induced bone formation in an

191 ratide once daily, and 214 received 10 mg of alendronate once daily.

192 of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo

193 Furthermore, osteoclasts treated with alendronate or alphav reduced the formation of the seali

194 viously reported that subjects randomized to alendronate or calcitriol immediately after cardiac tran

195 on, we evaluated the effect of discontinuing alendronate or calcitriol on bone loss and biochemical m

196 bjects who completed the randomized trial on alendronate or calcitriol, and in reference subjects who

197 After discontinuing alendronate or calcitriol, BMD remained stable during th

198 -1.5) were randomized to receive once-weekly alendronate or placebo in a double-blind cross-over stud

199 were randomized to receive 70 mg per week of alendronate or placebo over 1 year.

200 daily for 2 weeks were randomized to receive alendronate or placebo while initiating salmeterol for 8

201 n the ORs estimated according with BPs type (alendronate or risedronate) and regimen (daily or weekly

202 sed pharmaceutical inhibitors, atorvastatin, alendronate or zaragozic acid to inhibit the activity of

203 onate but prevented the inhibitory effect of alendronate or zoledronate on Rap1A prenylation.

204 s greatly decreased by OPG but not by either alendronate or zoledronate.

205 nefits are retained after discontinuation of alendronate or zoledronic acid, drug holidays after 5 ye

206 aneous injections of enoxacin, bis-enoxacin, alendronate, or doxycycline were administered for 6 week

207 fter treatment of animals with vehicle, OPG, alendronate, or zoledronate.

208 The B2AR signaling ratio was 0.89 for alendronate (P = .43) and 1.02 for placebo (P = .84; P =

209 A treatment ratio of B2AR number was 1.0 for alendronate (P = .86) and 0.8 for placebo (P = .15; P =

210 We identified 283,586 alendronate patients and 40,463 raloxifene patients.

211 046) was also observed in the femoral BMD of alendronate patients versus placebo.

212 factor of 2.6 in patients receiving 10 mg of alendronate per day for 3 years as compared with the pla

213 During the open-label alendronate period, adjudicated events of osteonecrosis

214 rtantly, we also found that PLN-encapsulated alendronate (PLN-alen), but not free alendronate, abroga

215 alendronate for at least 1 year to continued alendronate plus parathyroid hormone (1-34) subcutaneous

216 rmone (1-34) subcutaneously daily, continued alendronate plus parathyroid hormone (1-34) subcutaneous

217 Combined treatment of prednisolone and alendronate provided best improvement in muscle patholog

218 A second year of alendronate provides additional skeletal benefit, wherea

219 isk for nonvertebral fractures compared with alendronate recipients.

220 (HR, 1.78 [CI, 1.20 to 2.63]) compared with alendronate recipients.

221 In women with osteoporosis, 4 years of alendronate reduced clinical fractures (hazard ratio [HR

222 This study did not find evidence that alendronate reduces LABA-associated LOBP, which relates

223 < 0.05), whereas E2, raloxifene, EM652, and alendronate regulated 613, 765, 652, and 737 probe sets,

224 tives of this study are to determine whether alendronate remained in demineralized bone matrix (DBM)

225 The discontinuation of alendronate resulted in a gradual loss of effect, as mea

226 osozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fr

227 The discontinuation of alendronate resulted in the gradual loss of its effects.

228 Good evidence suggests that alendronate, risedronate, and estrogen prevent hip fract

229 linicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab

230 ral fractures (5.3% for placebo and 2.4% for alendronate; RR, 0.45; 95% CI, 0.24-0.85) but no signifi

231 al fractures (11.3% for placebo and 9.8% for alendronate; RR, 0.86; 95% CI, 0.60-1.22).

232 indicating the need for pre-osteoclasts for alendronate's effects.

233 study assesses the effects of topical sodium alendronate (SA) as an adjuvant to the mechanical treatm

234 In-vitro studies showed that alendronate SAMs induce differentiation of hMSC to a bon

235 ion, in patients with PBC-related bone loss, alendronate significantly improves BMD compared with pla

236 The use of alendronate significantly mitigated the bone loss.

237 potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic

238 detected in any of the DBM samples soaked in alendronate solutions.

239 Alendronate stimulated EphB1 and EphB3 protein expressio

240 eficient receptor down-regulation induced by alendronate, suggesting that FDPS regulates receptor dow

241 In addition, E2 and alendronate suppressed a cluster of genes associated wit

242 Alendronate suppressed the expression of bone sialoprote

243 Compared with continuing alendronate, switching to placebo for 5 years resulted i

244 te for at least 3 years before screening and alendronate the year before screening; an areal BMD T sc

245 Over two years, alendronate therapy after parathyroid hormone therapy le

246 for the strategy of a BMD test and selective alendronate therapy for patients with osteoporosis and u

247 te therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or u

248 Alendronate therapy for postmenopausal women with femora

249 sity (BMD) before initiating ADT followed by alendronate therapy in men with localized prostate cance

250 edronic acid, drug holidays after 5 years of alendronate therapy or 3 years of zoledronic acid therap

251 Five years of alendronate therapy or no drug treatment.

252 The ICER for universal alendronate therapy without a BMD test decreased to $100

253 for patients with osteoporosis and universal alendronate therapy without a BMD test were $66,800 per

254 for patients with osteoporosis, or universal alendronate therapy without a BMD test.

255 No BMD test or alendronate therapy, a BMD test followed by selective al

256 Thus, alendronate, through its direct effects on the pre-osteo

257 acebo-controlled, dose-ranging trial of oral alendronate to prevent bone resorption among healthy pos

258 vidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older pat

259 up (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 pat

260 romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [

261 p versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% low

262 t each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral

263 Alendronate-treated patients sustained less bone loss at

264 Alendronate treatment did not ameliorate muscle degenera

265 , the physiological target of beta-agonists, alendronate treatment functionally reversed agonist-indu

266 clasts with 20 to 40 nuclei were found after alendronate treatment had been discontinued for 1 year.

267 To investigate whether alendronate treatment in older patients using oral predn

268 Long-term alendronate treatment is associated with an increase in

269 using medium to high doses of prednisolone, alendronate treatment was associated with a significantl

270 Alendronate treatment was not associated with increased

271 nts with persistent osteoporosis after prior alendronate treatment, both daily treatment and cyclic t

272 Conversely, alendronate treatment, which restricts osteoclast activi

273 Both alendronate use and estrogen use were associated with si

274 ing was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone w

275 confidence interval [CI], 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to

276 d 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial.

277 Alendronate vs no alendronate use; no patients had previously taken alendr

278 95% confidence interval [CI] 0.94-1.13), but alendronate users are more likely to have vertebral frac

279 l4V alloy by chemisorption of osseoinductive alendronate using a simple, effective and clean methodol

280 of this study was to compare the effects of alendronate versus placebo on BMD and biochemical measur

281 Alendronate vs no alendronate use; no patients had previ

282 mild upper gastrointestinal tract symptoms (alendronate vs no alendronate, 15.6 [95% CI, 11.6-21.0]

283 The use of alendronate was associated with a lower risk of hip frac

284 The highest uptake of (64)Cu-DOTA-alendronate was in malignant tumors and the lowest uptak

285 Residual alendronate was not detected in the DBM from either grou

286 Results:(64)Cu-DOTA-alendronate was radiolabeled with a 98% yield.

287 DOTA-alendronate was synthesized, radiolabeled with (64)Cu, a

288 Alendronate was the reference category in all analyses.

289 fected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concern

290 and adolescents with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concern

291 e risk between risedronate or raloxifene and alendronate were small.

292 The therapeutic effects of alendronate were sustained, and the drug was well tolera

293 ction in bone turnover markers compared with alendronate; when women treated with alendronate are swi

294 tibiotic activities, was more effective than alendronate, which acts only as an antiresorptive.

295 hypothesized that subjects who discontinued alendronate, which has a long half-life in bone, would n

296 We conducted a randomized trial comparing alendronate with calcitriol for the prevention of bone l

297 e of the study compared three daily doses of alendronate with placebo.

298 Routine use of alendronate without a BMD test is justifiable in patient

299 When covalently conjugated to alendronate, YLLs acquire an additional function resulti

300 ements of side-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate on bone show t